LIGAND PHARMACEUTICALS

Reardon Andrew’s $52.27 buy of 5,000 LIGAND shares shows insider confidence, backing a bullish outlook amid analyst upgrades and a strong pipeline.

Insider trades at Ligand reveal routine portfolio rebalancing, not a shift in confidence. Watch for future moves that could hint at price upside.

Insider Aryeh Jason’s zero‑cost RSU purchase of 836 Ligand shares signals confidence in the drugmaker’s growth and offers investors a bullish insider signal amid strong 2026 performance.